Quality of response in acute myeloid leukemia: The role of minimal residual disease

Luca Maurillo, Renato Bassan, Nicola Cascavilla, Fabio Ciceri

Research output: Contribution to journalReview articlepeer-review


In the acute myeloid leukemia (AML) setting, research has extensively investigated the existence and relevance of molecular biomarkers, in order to better tailor therapy with newly developed agents and hence improve outcomes and/or save the patient from poorly effective therapies. In particular, in patients with AML, residual disease after therapy does reflect the sum of the contributions of all factors associated with diagnosis and post-diagnosis resistance. The evaluation of minimal/measurable residual disease (MRD) can be considered as a key tool to guide patient’s management and a promising endpoint for clinical trials. In this narrative review, we discuss MRD evaluation as biomarker for tailored therapy in AML patients; we briefly report current evidence on the use of MRD in clinical practice, and comment on the potential ability of MRD in the assessment of the efficacy of new molecules.

Original languageEnglish
Article number1417
Issue number10
Publication statusPublished - Oct 1 2019


  • Acute myeloid leukemia
  • Minimal residual disease
  • Tailored therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Quality of response in acute myeloid leukemia: The role of minimal residual disease'. Together they form a unique fingerprint.

Cite this